Skip to main content
Top
Published in: BMC Neurology 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Research article

Application of artificial neural network model in diagnosis of Alzheimer’s disease

Authors: Naibo Wang, Jinghua Chen, Hui Xiao, Lei Wu, Han Jiang, Yueping Zhou

Published in: BMC Neurology | Issue 1/2019

Login to get access

Abstract

Background

Alzheimer’s disease has become a public health crisis globally due to its increasing incidence. The purpose of this study was to establish an early warning model using artificial neural network (ANN) for early diagnosis of AD and to explore early sensitive markers for AD.

Methods

A population based nested case-control study design was used. 89 new AD cases with good compliance who were willing to provide urine and blood specimen were selected from the cohort of 2482 community-dwelling elderly aged 60 years and over from 2013 to 2016. For each case, two controls living nearby were identified. Biomarkers for AD in urine and blood, neuropsychological functions and epidemiological parameters were included to analyze potential risk factors of AD. Compared with logistic regression, k-Nearest Neighbor (kNN) and support vector machine (SVM) model, back-propagation neural network of three-layer topology structures was applied to develop the early warning model. The performance of all models were measured by sensitivity, specificity, accuracy, positive prognostic value (PPV), negative prognostic value (NPV), the area under curve (AUC), and were validated using bootstrap resampling.

Results

The average age of AD group was about 5 years older than the non-AD controls (P < 0.001). Patients with AD included a significantly larger proportion of subjects with family history of dementia, compared with non-AD group. After adjusting for age and gender, the concentrations of urinary AD7c-NTP and aluminum in blood were significantly higher in AD group than non-AD group (2.01 ± 1.06 vs 1.03 ± 0.43, 1.74 ± 0.62 vs 1.24 ± 0.41 respectively), but the concentration of Selenium in AD group (2.26 ± 0.59) was significantly lower than that in non-AD group (2.61 ± 1.07). All the models were established using 18 variables that were significantly different between AD patients and controls as independent variables. The ANN model outperformed the other classifiers. The AUC for this ANN was 0.897 and the model obtained the accuracy of 92.13%, the sensitivity of 87.28% and the specificity of 94.74% on the average.

Conclusions

Increased risk of AD may be associated with higher age among senior citizens in urban communities. Urinary AD7c-NTP is clinically valuable for the early diagnosis. The established ANN model obtained a high accuracy and diagnostic efficiency, which could be a low-cost practicable tool for the screening and diagnosis of AD for citizens.
Literature
1.
go back to reference Gaugler J, James B, Johnson T, et al. 2016 Alzheimer's disease facts and figures [J]. Alzheimers Dement. 2016;12(4):459–509.CrossRef Gaugler J, James B, Johnson T, et al. 2016 Alzheimer's disease facts and figures [J]. Alzheimers Dement. 2016;12(4):459–509.CrossRef
2.
go back to reference Appleby BS, Nacopoulos D, Milano N, et al. A review: treatment of Alzheimer’s disease discovered in repurposed agents [J]. Dement Geriatr Cogn Disord. 2013;35(1–2):1–22.PubMedCrossRef Appleby BS, Nacopoulos D, Milano N, et al. A review: treatment of Alzheimer’s disease discovered in repurposed agents [J]. Dement Geriatr Cogn Disord. 2013;35(1–2):1–22.PubMedCrossRef
3.
go back to reference Cerman E, Eraslan M, Cekic O. Age-related macular degeneration and Alzheimer disease [J]. Turk J Med Sci. 2015;45(5):1004–9.PubMedCrossRef Cerman E, Eraslan M, Cekic O. Age-related macular degeneration and Alzheimer disease [J]. Turk J Med Sci. 2015;45(5):1004–9.PubMedCrossRef
4.
go back to reference Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women [J]. Neurology. 2004;63(1):101–7.PubMedCrossRef Kang JH, Weuve J, Grodstein F. Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women [J]. Neurology. 2004;63(1):101–7.PubMedCrossRef
5.
6.
go back to reference Bemelmans SASA, Tromp K, Bunnik EM, et al. Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review [J]. Alzheimers Res Ther. 2016;8:46.PubMedPubMedCentralCrossRef Bemelmans SASA, Tromp K, Bunnik EM, et al. Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review [J]. Alzheimers Res Ther. 2016;8:46.PubMedPubMedCentralCrossRef
7.
go back to reference Herrmann N, Harimoto T, Balshaw R, et al. Risk factors for progression of Alzheimer disease in a Canadian population: the Canadian outcomes study in dementia (COSID)[J]. Can J Psychiatr. 2015;60(4):189–99.CrossRef Herrmann N, Harimoto T, Balshaw R, et al. Risk factors for progression of Alzheimer disease in a Canadian population: the Canadian outcomes study in dementia (COSID)[J]. Can J Psychiatr. 2015;60(4):189–99.CrossRef
8.
go back to reference Weuve J, Hebert LE, Scherr PA, et al. Prevalence of Alzheimer disease in US states [J]. Epidemiology. 2015;26(1):e4–6.PubMedCrossRef Weuve J, Hebert LE, Scherr PA, et al. Prevalence of Alzheimer disease in US states [J]. Epidemiology. 2015;26(1):e4–6.PubMedCrossRef
9.
go back to reference Robertson IH. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease [J]. Neurobiol Aging. 2013;34(1):298–308.PubMedCrossRef Robertson IH. A noradrenergic theory of cognitive reserve: implications for Alzheimer's disease [J]. Neurobiol Aging. 2013;34(1):298–308.PubMedCrossRef
10.
go back to reference Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer' s amyloid beta-peptide [J]. Nat Rev Mol Cell Biol. 2007;8(2):101–12.PubMedCrossRef Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer' s amyloid beta-peptide [J]. Nat Rev Mol Cell Biol. 2007;8(2):101–12.PubMedCrossRef
11.
go back to reference Almeida RP, Schultz SA, Austin BP, et al. Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease [J]. Jama Neurology. 2015;72(6):699–706.PubMedPubMedCentralCrossRef Almeida RP, Schultz SA, Austin BP, et al. Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease [J]. Jama Neurology. 2015;72(6):699–706.PubMedPubMedCentralCrossRef
12.
go back to reference Aggarwal NT, Shah RC, Bennett DA. Alzheimer's disease: unique markers for diagnosis & new treatment modalities [J]. Indian J Med Res. 2015;142(4):369–82.PubMedPubMedCentralCrossRef Aggarwal NT, Shah RC, Bennett DA. Alzheimer's disease: unique markers for diagnosis & new treatment modalities [J]. Indian J Med Res. 2015;142(4):369–82.PubMedPubMedCentralCrossRef
13.
go back to reference Lim YY, Villemagne VL, Pietrzak RH, et al. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease [J]. Neurobiol Aging. 2015;36(3):1239–44.PubMedCrossRef Lim YY, Villemagne VL, Pietrzak RH, et al. APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease [J]. Neurobiol Aging. 2015;36(3):1239–44.PubMedCrossRef
14.
go back to reference Almeida RP, Schultz SA, Austin BP, et al. Cognitive reserve and age-related changes in Alzheimer disease [J]. Jama Neurology. 2015;72(6):935–8.CrossRef Almeida RP, Schultz SA, Austin BP, et al. Cognitive reserve and age-related changes in Alzheimer disease [J]. Jama Neurology. 2015;72(6):935–8.CrossRef
15.
go back to reference Wang SH, Du S, Zhang Y, et al. Alzheimer's disease detection by Pseudo Zernike moment and linear regression classification [J]. CNS & Neurol Disord Drug Targets. 2017;16(1):11–5.CrossRef Wang SH, Du S, Zhang Y, et al. Alzheimer's disease detection by Pseudo Zernike moment and linear regression classification [J]. CNS & Neurol Disord Drug Targets. 2017;16(1):11–5.CrossRef
16.
go back to reference Zhang Y, Dong Z, Phillips P, et al. Detection of subjects and brain regions related to Alzheimer's disease using 3D MRI scans based on eigenbrain and machine learning [J]. Front Comput Neurosci. 2015;9(9):66.PubMedPubMedCentral Zhang Y, Dong Z, Phillips P, et al. Detection of subjects and brain regions related to Alzheimer's disease using 3D MRI scans based on eigenbrain and machine learning [J]. Front Comput Neurosci. 2015;9(9):66.PubMedPubMedCentral
17.
go back to reference Wang S, Zhang Y, Liu G, et al. Detection of Alzheimer's disease by three-dimensional displacement field estimation in structural magnetic resonance imaging [J]. Journal of Alzheimers Disease Jad. 2015;50(1):233–48.CrossRef Wang S, Zhang Y, Liu G, et al. Detection of Alzheimer's disease by three-dimensional displacement field estimation in structural magnetic resonance imaging [J]. Journal of Alzheimers Disease Jad. 2015;50(1):233–48.CrossRef
18.
go back to reference Hwang YN, Lee JH, Kim GY, et al. Classification of focal liver lesions on ultrasound images by extracting hybrid textural features and using an artificial neural network [J]. Biomed Mater Eng. 2015;26(s1):S1599–611.PubMed Hwang YN, Lee JH, Kim GY, et al. Classification of focal liver lesions on ultrasound images by extracting hybrid textural features and using an artificial neural network [J]. Biomed Mater Eng. 2015;26(s1):S1599–611.PubMed
19.
go back to reference Tang J, Wu L, Huang H, et al. Back propagation artificial neural network for community Alzheimer's disease screening in China [J]. Neural Regen Res. 2013;8(3):270–6.PubMedPubMedCentral Tang J, Wu L, Huang H, et al. Back propagation artificial neural network for community Alzheimer's disease screening in China [J]. Neural Regen Res. 2013;8(3):270–6.PubMedPubMedCentral
20.
go back to reference Tamaoka A. [Alzheimer's disease: definition and National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)][J]. Nihon Rinsho. 2011;69(Suppl 10(Pt 2)):240–5.PubMed Tamaoka A. [Alzheimer's disease: definition and National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)][J]. Nihon Rinsho. 2011;69(Suppl 10(Pt 2)):240–5.PubMed
21.
go back to reference Goh ATC. Back-propagation neural networks for modeling complex systems [J]. Artif Intell Eng. 1995;9(3):143–51.CrossRef Goh ATC. Back-propagation neural networks for modeling complex systems [J]. Artif Intell Eng. 1995;9(3):143–51.CrossRef
22.
go back to reference Prins ND, van der Flier WM, Brashear HR, et al. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population [J]. J Alzheimers Dis. 2013;36(1):79–85.PubMedCrossRef Prins ND, van der Flier WM, Brashear HR, et al. Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population [J]. J Alzheimers Dis. 2013;36(1):79–85.PubMedCrossRef
23.
go back to reference Huang HL, Lei WU, Yi-Feng WU, et al. Epidemiological analysis for community Alzheimer' s patients and their related elements, neurotransmitter in blood [J]. Chin J Dis Control Prev. 2012;16(5):382–7. Huang HL, Lei WU, Yi-Feng WU, et al. Epidemiological analysis for community Alzheimer' s patients and their related elements, neurotransmitter in blood [J]. Chin J Dis Control Prev. 2012;16(5):382–7.
24.
go back to reference Mcdowell I, Xi G, Lindsay J, et al. Mapping the connections between education and dementia [J]. J Clin Exp Neuropsychol. 2007;29(2):127–41.PubMedCrossRef Mcdowell I, Xi G, Lindsay J, et al. Mapping the connections between education and dementia [J]. J Clin Exp Neuropsychol. 2007;29(2):127–41.PubMedCrossRef
25.
go back to reference Li JQ, Tan L, Wang HF, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies [J]. J Neurol Neurosurg Psychiatry. 2015;87(5):476–84.PubMedCrossRef Li JQ, Tan L, Wang HF, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies [J]. J Neurol Neurosurg Psychiatry. 2015;87(5):476–84.PubMedCrossRef
26.
go back to reference Hughes TF, Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia [J]. Curr Psychiatr Rev. 2009;5(2):73–92.CrossRef Hughes TF, Ganguli M. Modifiable midlife risk factors for late-life cognitive impairment and dementia [J]. Curr Psychiatr Rev. 2009;5(2):73–92.CrossRef
27.
go back to reference Bherer L, Erickson KI, Liu-Ambrose T. A review of the effects of physical activity and exercise on cognitive and brain functions in older adults [J]. J Aging Res. 2013;2013:657508.PubMedPubMedCentral Bherer L, Erickson KI, Liu-Ambrose T. A review of the effects of physical activity and exercise on cognitive and brain functions in older adults [J]. J Aging Res. 2013;2013:657508.PubMedPubMedCentral
28.
go back to reference Noice T, Noice H, Kramer AF. Participatory arts for older adults: a review of benefits and challenges [J]. Gerontologist. 2014;54(5):741–53.PubMedCrossRef Noice T, Noice H, Kramer AF. Participatory arts for older adults: a review of benefits and challenges [J]. Gerontologist. 2014;54(5):741–53.PubMedCrossRef
29.
go back to reference Esteve M E, Gil A C. [Reading as a protective factor against cognitive decline][J]. Gac Sanit 2013;27(1):68–71. Esteve M E, Gil A C. [Reading as a protective factor against cognitive decline][J]. Gac Sanit 2013;27(1):68–71.
30.
go back to reference Guéroux M, Pinaud-Szlosek M, Fouquet E, et al. How wine polyphenols can fight Alzheimer disease progression: towards a molecular explanation [J]. Tetrahedron. 2015;71(20):3163–70.CrossRef Guéroux M, Pinaud-Szlosek M, Fouquet E, et al. How wine polyphenols can fight Alzheimer disease progression: towards a molecular explanation [J]. Tetrahedron. 2015;71(20):3163–70.CrossRef
31.
go back to reference Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain [J]. Biochim Biophys Acta. 2014;1842(9):1693–706.PubMedPubMedCentralCrossRef Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain [J]. Biochim Biophys Acta. 2014;1842(9):1693–706.PubMedPubMedCentralCrossRef
32.
go back to reference Sebastiao I, Candeias E, Santos MS, et al. Insulin as a bridge between type 2 diabetes and Alzheimer disease - how anti-diabetics could be a solution for dementia. [J] Front Endocrinol (Lausanne). 2014;5:110. Sebastiao I, Candeias E, Santos MS, et al. Insulin as a bridge between type 2 diabetes and Alzheimer disease - how anti-diabetics could be a solution for dementia. [J] Front Endocrinol (Lausanne). 2014;5:110.
33.
go back to reference Sweet RA, Bennett DA, Graffradford NR, et al. Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging late onset Alzheimer’s disease family study [J]. Brain. 2010;133(4):1155–62.PubMedPubMedCentralCrossRef Sweet RA, Bennett DA, Graffradford NR, et al. Assessment and familial aggregation of psychosis in Alzheimer’s disease from the National Institute on Aging late onset Alzheimer’s disease family study [J]. Brain. 2010;133(4):1155–62.PubMedPubMedCentralCrossRef
34.
go back to reference Feldman AL, Johansson AL, Lambert PC, et al. Familial coaggregation of Alzheimer's disease and Parkinson's disease: systematic review and meta-analysis [J]. Neuroepidemiology. 2014;42(2):69–80.PubMedCrossRef Feldman AL, Johansson AL, Lambert PC, et al. Familial coaggregation of Alzheimer's disease and Parkinson's disease: systematic review and meta-analysis [J]. Neuroepidemiology. 2014;42(2):69–80.PubMedCrossRef
36.
go back to reference Hao JH, Jiang LI, He L. The detection and significance of urinary AD7c-NTP in patients with Alzhemier disease [J]. China Trop Med. 2011;11(08):993–4. Hao JH, Jiang LI, He L. The detection and significance of urinary AD7c-NTP in patients with Alzhemier disease [J]. China Trop Med. 2011;11(08):993–4.
37.
go back to reference Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma proteins predict conversion to dementia from prodromal disease [J]. Alzheimers Dement. 2014;10(6):799–807.PubMedPubMedCentralCrossRef Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma proteins predict conversion to dementia from prodromal disease [J]. Alzheimers Dement. 2014;10(6):799–807.PubMedPubMedCentralCrossRef
38.
go back to reference Grossi E, Buscema MP, Snowdon D, et al. Neuropathological findings processed by artificial neural networks (ANNs) can perfectly distinguish Alzheimer's patients from controls in the Nun study [J]. BMC Neurol. 2007;7(1):1–7.CrossRef Grossi E, Buscema MP, Snowdon D, et al. Neuropathological findings processed by artificial neural networks (ANNs) can perfectly distinguish Alzheimer's patients from controls in the Nun study [J]. BMC Neurol. 2007;7(1):1–7.CrossRef
Metadata
Title
Application of artificial neural network model in diagnosis of Alzheimer’s disease
Authors
Naibo Wang
Jinghua Chen
Hui Xiao
Lei Wu
Han Jiang
Yueping Zhou
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2019
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-019-1377-4

Other articles of this Issue 1/2019

BMC Neurology 1/2019 Go to the issue